Feedback inhibition by 6-methylthioinosine 3',5'-cyclic monophosphate in tumor cells resistant to the nucleoside.
The 3',5'-cyclic phosphate derivative (cMTIMP) of methylthioinosine (MTI) was shown to produce feedback inhibition of the de novo purine pathway in an Ehrlich ascites tumor subline resistant to MTI because of lack of adenosine kinase activity for the nucleoside analog.
D000241:Adenosine / Q000627:therapeutic use; D000248:Adenosine Kinase / Q000037:antagonists & inhibitors; D000818:Animals; D001667:Binding, Competitive; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D007288:Inosine / Q000031:analogs & derivatives*; D008778:Methylthioinosine / Q000627:therapeutic use*; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009712:Nucleotides, Cyclic / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011687:Purines / Q000096:biosynthesis
D009712:Nucleotides, Cyclic; D010726:Phosphodiesterase Inhibitors; D011687:Purines; D008778:Methylthioinosine; D007288:Inosine; D000248:Adenosine Kinase; D010727:Phosphoric Diester Hydrolases; D000241:Adenosine